Ultima-Tirzepatide

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GIP/GLP-1 RA

Introducing Tirzepatide, a groundbreaking synthetic peptide designed to effectively manage blood sugar levels. By stimulating insulin secretion during the initial and subsequent phases and lowering glucagon levels in direct response to glucose fluctuations, Tirzepatide sets a new standard in diabetes care.

This innovative treatment also slows gastric emptying, reduces both fasting and post-meal glucose levels, curbs appetite, and supports weight loss for individuals battling type 2 diabetes. Furthermore, it enhances insulin sensitivity, making it a comprehensive solution for glucose management.

What sets Tirzepatide apart is its unique structural design: it is linked to a C20 fatty diacid through a hydrophilic connector at the lysine position 20, which facilitates robust binding to albumin in the bloodstream, thereby extending its active half-life.

GLP-1 (glucagon-like peptide-1) receptors (GLP-1R) are strategically located throughout the body, including in pancreatic beta-cells and the gastrointestinal tract, playing a pivotal role in the pathophysiology of type 2 diabetes. GLP-1R signaling is crucial for regulating blood sugar levels by boosting insulin secretion in response to glucose, delaying gastric emptying, lowering glucagon levels, and promoting weight loss through appetite suppression pathways in the brain. Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are essential peptide hormones that maintain glucose homeostasis by stimulating insulin release from pancreatic beta-cells, with GIP being the primary incretin hormone post-meal.

While the exact mechanisms of Tirzepatide are still under investigation, its dual activation of GIP and GLP-1 receptors is likely integral to its blood sugar-lowering and weight management capabilities. Research suggests that the combination of GIP and GLP-1R agonism yields a more pronounced insulin response and glucagon suppression compared to either hormone alone. Tirzepatide demonstrates a strong binding affinity to both GIP and GLP-1R, exhibiting comparable affinity for GIP receptors as native GIP, while its affinity for GLP-1R is five times lower than that of native GLP-1. By effectively activating GLP-1R signaling, Tirzepatide promotes glucose-dependent insulin secretion via either the GIP receptor (GIPR) or the GLP-1R. Nonetheless, further research is needed to fully understand the role of GIPR activation in Tirzepatide's mechanism, as findings regarding its impact on blood sugar and weight control vary across preclinical and clinical studies.